Both in Pharmaceuticals
Akebia Therapeutics vs Cartesian Therapeutics
Over the past year AKBA returned −65.8% and RNAC returned −16.7%; their daily moves had a correlation of 0.24.
AKBA −65.8% RNAC −16.7%Growth of $1, one year, split-adjusted
| Metric | AKBA | RNAC |
|---|---|---|
| Price | $0.7252 | $6.77 |
| Market cap | $201.0M | $204.8M |
| Today | −0.08% | +5.62% |
| 1 month | −17.5% | +0.3% |
| 6 months | −51.0% | −18.8% |
| Year to date | −55.0% | −6.1% |
| 1 year | −65.8% | −16.7% |
| Revenue growth (YoY) | −21.4% | −100.0% |
| Gross margin | 78.8% | — |
| Net margin | −18.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 0.9× | 138.7× |
| Net cash | $106.0M | $94.8M |
| Dividend yield | — | — |
| Volatility (60d) | 71.8% | 50.4% |
| Short % of float | 8.7% | 15.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).